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Abstract: The aim of this study was to evaluate the real-life immunogenicity of anti-drug 
antibodies, drug levels, and disease activity in an Italian cohort of rheumatoid arthritis patients 
treated with tocilizumab (TCZ). We evaluated 126 TCZ-treated patients with rheumatoid arthritis 
(16 males and 110 females; mean age 59±12 years, range 26–83; mean disease duration 11±5 
years) with inadequate 12-week response to any synthetic and biological disease-modifying 
anti-rheumatic drugs, in a retrospective analysis. One-hundred and seven patients were treated 
with methotrexate mean dose 12.6±1.3 mg/week in combination with TCZ, 13 received TCZ 
monotherapy, and six received leflunomide 20 mg/day plus TCZ; all patients were treated with 
prednisone mean dose 6.4±1.2 mg/day. They had a 28-joint Disease Activity Score (DAS28) of 
.3.2, an erythrocyte sedimentation rate (ESR) of .30 mm/hour, and CRP levels of .1.0 mg/dL. 
We evaluated at baseline and after 6 months of treatment: DAS28; rheumatoid factor (RF) IgM, 
IgA, and IgG; anti-citrullinated peptide antibody; ESR; CRP; TNF-α; and IL-6. TCZ and anti-
TCZ antibodies were detected using LISA-TRACKER Duo TCZ. TCZ levels of ,10 µg/mL were 
considered low and .10 µg/mL high. After 6 months of treatment only one patient was positive 
for anti-TCZ antibodies. There were correlations between DAS28, ESR, and CRP and IL-6 levels 
in all patients. Comparison of the 84 patients with TCZ levels of ,10 µg/mL and the 42 with 
TCZ levels of .10 µg/mL showed the following differences: DAS28: 3.09±1.32 vs 2.78±1.32, 
P=0.0005; ESR: 27±14.8 vs 14±12 mm/hour, P=0.0001; CRP: 1.47±1.05 vs 0.65±0.80 mg/dL, 
P=0.0086; TNF-α: 10.2±1.2 vs 9.9±1.1 pg/mL, P=0.999; IL-6: 3.65±4.75 vs 3.62±4.41 pg/mL, 
P=0.97; anti-citrullinated peptide antibody: 85.2±93.7 vs 86.7±90.3 IU/mL, P=0.94; RF IgM: 
72.4±62.7 vs 68.3±61.6 IU/mL, P=0.754; RF IgA: 41.7±36.4 vs 47.8±42.1 U/mL, P=0.449; 
and RF IgG: 46.4±46.1 vs 59.3±58.2 U/mL, P=0.212. These findings show that the occurrence 
of anti-drug antibodies against TCZ is very rare and that there are statistically significant cor-
relations between TCZ levels of .10 µg/mL and ESR, CRP levels, and DAS28.
Keywords: tocilizumab, TCZ drug level, antibodies anti-TCZ
Introduction
IL-6 is a multifunctional, pro-inflammatory cytokine that regulates inflammation, 
hematopoiesis, and the immune response, and is over-expressed in a number of inflam-
matory diseases, including rheumatoid arthritis (RA). It plays a central role in the 
pathogenesis of RA and its multiple functions contribute to both systemic and arthritic 
disease signs and symptoms, as well as the joint destruction associated with a poor func-
tional status and disability.1,2 Increased IL-6 levels correlate with high CRP, SAA, and 
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rheumatoid factor (RF) levels, and erythrocyte sedimentation 
rate (ESR),3,4 and are associated with clinical outcomes such 
as radiographic changes, the number of affected joints, and 
the duration of morning stiffness.5,6 Tocilizumab (TCZ) is a 
humanized anti-IL-6R monoclonal antibody that competitively 
inhibits the binding of IL-6 to both mIL-6R and sIL-6R, thus 
preventing the activation of gp130 and inhibiting pro-inflam-
matory cascade.7 It is efficacious and generally well tolerated 
in a wide range of patients with RA when given as mono-
therapy8 or in combination with methotrexate (MTX)9 and 
other disease-modifying anti-rheumatic drugs (DMARDs).10 
Studies showed that during treatment with anti-TNF drugs 
the antibody production against these drugs is frequent and 
affects safety and efficacy,11 but this is a rare event during TCZ 
therapy. The production of antibodies against TCZ was tested 
using the typical two-step approach: a highly specific, high-
throughput enzyme-linked immunosorbent assay (ELISA) 
with a bridging format for screening and confirming TCZ 
anti-drug antibodies (ADAs) that was theoretically capable 
of detecting all isotype responses, and secondary assays in 
order to characterize the neutralizing capacity of the ADAs, 
their immunoglobulin isotype, and their binding epitope.12,13 
Following a regulatory request regarding the TCZ development 
program, immunogenicity testing was introduced during the 
course of the ACT-RAY study, and the patients were tested for 
ADAs and neutralizing antibodies using the available baseline, 
week 24, and week 52 samples.14
The aim of this study was to evaluate TCZ ADA immuno-
genicity, drug levels, and disease activity in a real-life Italian 
cohort of TCZ-treated RA patients.
Materials and methods
We evaluated 126 patients (16 males and 110 females with a 
mean age of 59±12 years, range 26–83; disease duration 11±5 
years), who were diagnosed as having RA on the basis of the 
1987 American College of Rheumatology (ACR) criteria,15 and 
showed inadequate 12-week response to any synthetic (MTX, 
sulfasalazine, leflunomide) and biological DMARD (infliximab, 
etanercept, adalimumab). They had a 28-joint Disease Activity 
Score (DAS28) of .3.2, an ESR of .30 mm/hour, and CRP 
levels of .1.0 mg/dL. One-hundred and seven patients were 
treated with MTX (mean dose 12.6±1.3 mg/week) in combina-
tion with TCZ, 13 patients were receiving TCZ monotherapy, 
and six leflunomide 20 mg/day plus TCZ; all of the patients were 
treated with prednisone (mean dose 6.4±1.2 mg/day).
The following parameters were evaluated at baseline and 
after 6 months: DAS28; RF IgM (N Latex RF; Siemens AG, 
Munich, Germany), RF IgA and RF IgG (Enzyme Immuno 
Assay; Orgentec Diagnostika GmbH, Mainz, Germany); anti-
citrullinated peptide antibody (ACPA) (Anti-CCP EDIA™; 
Euro-Diagnostica, Malmö, Sweden); ESR (mm/hour); CRP 
(mg/dL); TNF-α (Human TNF-alpha Quantikine Immunoas-
say; R&D Systems, Inc., Minneapolis, MN, USA); and IL-6 
(Human IL6 Instant Enzyme-linked Immunosorbent Assay; e 
Bioscience, Bender MedSystems GmbH, Vienna, Austria). 
The ethical consent for this study was provided by the 
local ethics committee of Ospedale San Giovanni di Dio 
(Florence, Italy). Patient consent was not sought, owing to the 
retrospective nature of this study, which was carried out using 
leftover samples, with all analyses performed blindly, and as 
all patients’ records and information remained anonymous.
TcZ and anti-TcZ assay
All of the serum samples were analyzed for TCZ levels and 
anti-TCZ antibodies by Lisa Tacker Duo Tocilizumab (The-
radiag, Marne La Vallee, France). This ELISA system allows 
for the simultaneous detection of both drug and anti-drug 
antibodies, in a micro-well plate format in which half of the 
plate is coated with TNF-α, to measure TCZ concentration, 
and the other half is coated with TCZ, for ADA detection. 
Assays were carried out according to the manufacturer’s 
instruction. Optical density of each well was read at 450 
nm. A calibration range allows the quantity of TCZ in each 
sample to be expressed in µg/mL. TCZ levels of ,10 µg/
mL were considered low and .10 µg/mL high. Similarly, a 
calibration range allows the quantity of anti-TCZ antibodies 
in each sample to be expressed in ng/mL.
statistical analysis
Analysis of variance (ANOVA) was used in order to estab-
lish whether there were significant differences between 
the mean values of all the considered variables. ANOVA 
separates the variance of the data into between- and within-
group components, and F represents the ratio of the two 
estimates. If the F-test P-value is ,0.05, there is a statisti-
cally significant difference between the mean values of all 
of the variables at a significance level of 5%, and subsequent 
multiple range tests indicate which paired variables have 
significantly different mean values. It was first determined 
whether there were any significant differences in each vari-
able at T0 (baseline) and T6 (after 6 months of treatment) 
by gathering data for TCZ ,10 µg/mL and .10 µg/mL, 
and for RF-positivity and negativity. The data were analyzed 
using SAS statistical software, version 9.2 (SAS Institute 
Inc., Cary, NC, USA). A P-value of ,0.05 was considered 
significant.
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Results
After 6 months of treatment only one patient was positive for 
anti-TCZ antibodies with a value of 84 ng/mL. Among the 
patients as a whole, there were correlations between DAS28, 
ESR, and CRP and IL-6 levels (Figure 1). Two patients withdrew 
before week 24 due to inefficacy and one due to an adverse 
event (AE) (transaminases increased). Comparison of the 84 
patients with TCZ levels of ,10 µg/mL and the 42 with TCZ 
levels of .10 µg/mL showed the following differences: DAS28: 
3.09±1.32 vs 2.78±1.32, P=0.0005; ESR: 27±14.8 vs 14±12 mm/
hour, P=0.0001; CRP: 1.47±1.05 vs 0.65±0.80 mg/dL, P=0.0086; 
TNF: 10.2±1.2 vs 9.9±1.1 pg/mL, P=0.999; IL-6: 3.65±4.75 vs 
3.62±4.41 pg/mL, P=0.97; ACPA: 85.2±93.7 vs 86.7±90.3 IU/
mL, P=0.94; RF IgM: 72.4±62.7 vs 68.3±61.6 IU/mL, P=0.754; 
RF IgA: 41.7±36.4 vs 47.8±42.1 U/mL, P=0.449; and RF IgG: 
46.4±46.1 vs 59.3±58.2 U/mL, P=0.212 (Table 1).
Comparison of the 77 ACPA and RF IgM-positive 
patients and the 49 who were ACPA and RF IgM-negative 
did not reveal any differences in the clinical or serological 
parameters: DAS28: 2.82±1.34 vs 2.91±1.21, P=0,694; ESR: 
16.7±13.6 vs 18.7±15.6 mm/hour, P=0.483; CRP 0.91±0.85 
vs 0.81±0.91 mg/dL, P=0.713; TNF-α: 10.31±1.45 vs 
10.1±1.31 pg/mL, P=0.254; and IL-6: 3.57±5.40 vs 3.69±3 
pg/mL, P=0.888 (Table 2).
Discussion
The study results show that the occurrence of TCZ ADAs is 
very rare (only 1/126 patients after 6 months of treatment). 
This is in line with the findings of two other studies published 
this year: the first analyzed 90 samples and found that only 
three patients had transient ADAs (low titres, not observed 
3 months later);16 and the second found no case among 22 
patients (18 with RA, three with idiopathic juvenile arthritis, 
and one with adult-onset Still’s disease).17
One study has assessed the validity of ELISA for detect-
ing anti-TCZ antibodies using complementary bioanalytical 
assays to test samples from a subgroup of patients with 
clinical AEs of a potentially immunogenic nature, who 
were considered highly likely to have ADAs.18 The Phase 
III program for TCZ consisted of five core studies in which 
adult RA patients received TCZ 4 or 8 mg/kg intravenously 
or a control every 4 weeks, with or without concomitant 
anti-rheumatic therapy. These studies and their open-label, 
long-term extensions enrolled a total of 4,199 patients, and 
clinical AEs of a potentially immunogenic nature occurred 
in 21 patients during TCZ treatment, eight of whom had an 
anaphylactic reaction. Eleven of the samples from these 21 
patients had tested negative for ADAs upon ELISA screen-
ing, and only one tested positive in both subsequent assays; 
all of the others tested negative.18
In the ACT-RAY study, the patients were tested for ADAs 
and neutralizing antibodies using available baseline, week 24, 
and week 52 samples (or upon withdrawal before week 52). The 
rate of total and neutralizing ADAs (seroconversion in a neutral-
izing assay) was similar in the patients receiving TCZ mono-
therapy or TCZ plus MTX: 1.5%–2.2% and 0.7%–1.8%.14
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Figure 1 correlation between level of TcZ and clinical and laboratory parameters.
Note: T0, baseline; T6, after 6 months of treatment.
Abbreviations: LSD, least significant difference; RF, rheumatoid factor; TCZ, tocilizumab; ESR, erythrocyte sedimentation rate; DAS28, 28-joint Disease Activity Score; 
acPa, anti-citrullinated peptide antibody.
Biologics: Targets and Therapy 2016:10submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
56
Benucci et al
The long-term safety and efficacy study of subcutaneous 
TCZ monotherapy in RA patients found anti-TCZ antibodies 
in 2.1% of the patients after 108 weeks.19
Finally, the proportion of patients who developed anti-
TCZ antibodies in the SUMMACTA study of subcutaneous 
and intravenous TCZ were comparably low (1.6% and 1.1%) 
in both arms, including the switch arms, up to week 97, and 
there was no correlation between the development of anti-
TCZ antibodies and clinical response or AEs.20
We observed statistically signif icant correlations 
between TCZ levels of .10 µg/mL and ESR, CRP and 
DAS28. One study has found that trough serum TCZ 
levels are lower in patients with high disease activ-
ity (DAS28 .5.1) than in those in remission or those 
with low or moderate disease activity, all of whom had 
similar levels; none of the other patient parameters were 
significantly associated or correlated with trough serum 
TCZ levels.16
Another study found heterogeneous serum TCZ levels 
that did not correlate with disease activity but did correlate 
with CRP levels; the patients receiving DMARDs with or 
without glucocorticoids had higher TCZ levels.17
We did not find a correlation with IL-6 levels after 6 
months when the patients were subdivided on the basis of 
TCZ levels, but levels decreased in the patients as a whole. 
The low prevalence of TCZ ADAs may be a consequence 
Table 2 comparison of the 77 acPa and rF igM-positive patients and the 49 patients who were acPa and rF igM-negative
Parameters ACPA and RF positive patients (n=77, mean  ± SD) ACPA and RF negative patients (n=49, mean ± SD) P-value
Das28 T0 4.43±0.98 4.48±0.78 ns
Das28 T6 2.82±1.34 2.91±1.21 0.694
esr mm/hour T0 38.10±18.73 38.18±19.37 ns
esr mm/hour T6 16.7±13.6 18.7±15.6 0.483
crP mg/dl T0 4.15±6.09 2.57±2.05 ns
crP mg/dl T6 0.91±0.85 0.81±0.91 0.713
TnF-α pg/ml T0 14±8.1 12.6±7.38 ns
TnF-α pg/ml T6 10.31±1.45 10.1±1.31 0.254
il-6 pg/ml T0 12±7 7.7±2.9 ns
il-6 pg/ml T6 3.57±5.40 3.69±3 0.888
Note: T0, baseline; T6, after 6 months of treatment.
Abbreviations: ESR, erythrocyte sedimentation rate; DAS28, 28-joint Disease Activity Score; RF, rheumatoid factor; ACPA, anti-citrullinated peptide antibody; SD, standard 
deviation; ns, not significant.
Table 1 comparison of the 84 patients with TcZ levels of ,10 µg/ml and the 42 with TcZ levels of .10 µg/ml
Parameters Tocilizumab ,10 ug/mL (n=84, mean ± SD) Tocilizumab .10 ug/mL (n=42, mean ± SD) P-value
Das28 T0 4.31±0.98 4.33±0.93 ns
Das28 T6 3.09±1.32 2.78±1.32 0.0005
esr mm/hour T0 38±19 37±18.2 ns
esr mm/hour T6 27±14.8 14±12 0.0001
crP mg/dl T0 3.48±0.43 3.47±0.45 ns
crP mg/dl T6 1.47±1.05 0.65±0.80 0.0086
TnF-α pg/ml T0 10.2±1.1 10.3±0.9 ns
TnF-α pg/ml T6 10.2±1.2 9.9±1.1 0.999
il-6 pg/ml T0 10.2±1.2 10.3±1.3 ns
il-6 pg/ml T6 3.65±4.75 3.62±4.41 0.97
acPa iU/ml T0 91±98 91±96 ns
acPa iU/ml T6 85.2±93.7 86.7±90.3 0.94
rF igM iU/ml T0 78±86 77±84 ns
rF igM iU/ml T6 72.4±62.7 68.3±61.6 0.754
rF iga U/ml T0 47±46 48±46 ns
rF iga U/ml T6 41.7±36.4 47.8±42.1 0.449
rF igg U/ml T0 49±59 48±58 ns
rF igg U/ml T6 46.4±46.1 59.3±58.2 0.212
Note: T0, baseline; T6, after 6 months of treatment.
Abbreviations: TCZ, tocilizumab; ESR, erythrocyte sedimentation rate; DAS28, 28-joint Disease Activity Score; RF, rheumatoid factor; ACPA, anti-citrullinated peptide 
antibody; SD, standard deviation; ns, not significant.
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of a TCZ-induced IL-6 blockade acting on Tfh CD4 T cells 
and/or B cells at their different stages of differentiation and 
maturation. IL-6 is necessary and sufficient for IL-21 produc-
tion by memory and naïve CD4+ T cells, and recent studies 
have shown that IL-6 induces antibody production indirectly 
by acting on CD4+ T cells to promote production of high 
levels of IL-21 which in turn promotes B cell differentiation 
and increases antibody production.21
Conclusion
Our results confirm that the occurrence of TCZ ADAs is 
very rare, appearing in only one patient after 6 months of 
treatment. They also show statistically significant correla-
tions between TCZ levels of .10 µg/mL and ESR, CRP, 
and DAS28. However, these findings need to be validated 
by further studies.
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